Literature DB >> 22050384

Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation.

Roland Fenk, Florian Neubauer, Ingmar Bruns, Thomas Schröder, Ulrich Germing, Rainer Haas, Guido Kobbe.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22050384     DOI： 10.1111/j.1365-2141.2011.08905.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.

Authors:  Amrita Y Krishnan; Matthew Mei; Can-Lan Sun; Sandra H Thomas; Jennifer Berano Teh; Tongjun Kang; Myo Htut; George Somlo; Firoozeh Sahebi; Stephen J Forman; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-13       Impact factor: 5.742

2.  Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.

Authors:  Naveen Pemmaraju; Dhaval Shah; Hagop Kantarjian; Robert Z Orlowski; Graciela M Nogueras González; Veera Baladandayuthapani; Nitin Jain; Verena Wagner; Guillermo Garcia-Manero; Jatin Shah; Farhad Ravandi; Sherry Pierce; Koichi Takahashi; Naval Daver; Aziz Nazha; Srdan Verstovsek; Elias Jabbour; Marcos De Lima; Richard Champlin; Jorge Cortes; Muzaffar H Qazilbash
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-07-15

3.  Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study.

Authors:  I A Bilmon; L J Ashton; R E Le Marsney; A J Dodds; T A O'Brien; L Wilcox; I Nivison-Smith; B Daniels; C M Vajdic
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

4.  Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience.

Authors:  Tian-Jiao Guo; Xiao-Jun Huang; Lei Wen; Jin Lu
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

5.  Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.

Authors:  Rouslan Kotchetkov; Esther Masih-Khan; Chia-Min Chu; Eshetu G Atenafu; Christine Chen; Vishal Kukreti; Suzanne Trudel; Rodger Tiedemann; Donna E Reece
Journal:  Cancer Med       Date:  2016-11-18       Impact factor: 4.452

Review 6.  Second primary malignancies in multiple myeloma: A review.

Authors:  Christina Poh; Theresa Keegan; Aaron Seth Rosenberg
Journal:  Blood Rev       Date:  2020-09-06       Impact factor: 8.250

7.  Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study.

Authors:  Huey-En Tzeng; Cheng-Li Lin; Chun-Hao Tsai; Chih-Hsin Tang; Wen-Li Hwang; Ya-Wen Cheng; Fung-Chang Sung; Chi-Jung Chung
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

8.  Small-Sized Clone of T Cells in Multiple Myeloma Patient after Auto-SCT: T-LGL Leukemia Type or Clonal T-Cell Aberration?

Authors:  Giuseppe Mele; Marilena Greco; Maria Rosaria Coppi; Giacomo Loseto; Angela Melpignano; Salvatore Mauro; Gianni Quarta
Journal:  Case Rep Hematol       Date:  2013-04-21

9.  Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study.

Authors:  Mukta Arora; Yanjun Chen; Lindsey Hageman; Jessica Wu; Wendy Landier; Liton Francisco; Michelle Kung; Emily Ness; Alysia Bosworth; Merve Pamukcuoglu; Daniel J Weisdorf; Stephen J Forman; Saro H Armenian; Smita Bhatia
Journal:  Cancer       Date:  2020-05-15       Impact factor: 6.921

10.  Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups.

Authors:  S Ailawadhi; A Swaika; P Razavi; D Yang; A Chanan-Khan
Journal:  Blood Cancer J       Date:  2014-09-05       Impact factor: 11.037
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.